Latanoprost
Alternative Names: Latanoprost ophthalmic solution - Pfizer; PhXA41; XalatanLatest Information Update: 05 Nov 2023
At a glance
- Originator Pfizer
- Class Antiglaucomas; Eye disorder therapies; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Glaucoma; Ocular hypertension
Most Recent Events
- 27 Mar 2015 Latanoprost is approved in the European Union for Glaucoma and Ocular hypertension
- 05 Aug 2013 Bausch & Lomb has been acquired by Valeant Pharmaceuticals International
- 25 Jan 2012 Generic equivalent available in Italy, Spain, Iceland, Switzerland, Hungary, Bulgaria & Czech Republic